Published in Brain Pathol on July 01, 2003
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol (2006) 2.62
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener Dis (2010) 1.31
Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci (2013) 1.27
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology (2015) 1.21
Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol (2006) 1.16
Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol (2015) 1.15
Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease. PLoS One (2012) 1.09
Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol (2010) 1.07
Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis (2012) 1.04
Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol (2015) 1.03
Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord (2009) 0.97
Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord (2014) 0.93
Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol (2014) 0.89
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort. Clin Exp Med Sci (2013) 0.83
Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. J Parkinsons Dis (2012) 0.82
Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging (2014) 0.79
Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiol Aging (2016) 0.77
Hippocampal sclerosis dementia: An amnesic variant of frontotemporal degeneration. Dement Neuropsychol (2013) 0.76
Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol (2017) 0.75
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol (2006) 4.91
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol (2006) 4.25
Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med (2003) 3.78
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med (2007) 3.33
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A (2004) 2.88
Effects of various methodologic strategies: survey response rates among Canadian physicians and physicians-in-training. Can Fam Physician (2008) 2.76
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet (2004) 2.10
A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet (2006) 2.01
Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci (2006) 1.98
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. Brain (2006) 1.75
HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J (2006) 1.75
Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol (2010) 1.69
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (2006) 1.64
The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am (2002) 1.64
Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61
Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol (2003) 1.58
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem (2002) 1.57
Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia. Arch Neurol (2003) 1.55
Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci (2008) 1.54
Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis (2008) 1.52
Dissembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients. Mol Neurodegener (2009) 1.52
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A (2006) 1.52
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain (2006) 1.51
Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging (2005) 1.51
Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry (2002) 1.50
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology (2013) 1.50
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging (2012) 1.49
Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem (2005) 1.45
Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol (2011) 1.45
Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr Alzheimer Res (2006) 1.44
Security and privacy qualities of medical devices: an analysis of FDA postmarket surveillance. PLoS One (2012) 1.40
Identification of a novel family of presenilin homologues. Hum Mol Genet (2002) 1.40
Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch Neurol (2007) 1.39
An analysis of the causes of compressed-gas diving fatalities in Australia from 1972-2005. Undersea Hyperb Med (2013) 1.37
Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res (2007) 1.35
Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett (2010) 1.35
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol (2003) 1.34
Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Hum Mol Genet (2003) 1.32
Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener Dis (2010) 1.31
Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur J Neurosci (2007) 1.31
Sorl1 as an Alzheimer's disease predisposition gene? Neurodegener Dis (2007) 1.31
Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res (2004) 1.28
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion (2006) 1.25
Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet (2007) 1.24
Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging (2005) 1.24
Epidemiology and genetics of frontotemporal dementia/Pick's disease. Ann Neurol (2003) 1.24
Clinical features of pathologic subtypes of behavioral--variant frontotemporal dementia. Arch Neurol (2007) 1.22
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Attractiveness of family medicine for medical students: influence of research and debt. Can Fam Physician (2011) 1.19
A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett (2008) 1.17
A novel calcium-binding protein is associated with tau proteins in tauopathy. J Neurochem (2008) 1.16
Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J Pathol (2009) 1.15
Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet (2004) 1.13
In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem (2008) 1.13
ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci (2009) 1.12
Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol (2006) 1.11
Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau. J Neurocytol (2006) 1.11
Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. Proc Natl Acad Sci U S A (2005) 1.10
Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. Am J Pathol (2004) 1.09
The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. J Neurosci (2002) 1.08
Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Res Mol Brain Res (2005) 1.08
Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis (2008) 1.07
Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain (2014) 1.06
Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener (2010) 1.06
Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. Am J Pathol (2010) 1.06
Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol (2005) 1.05
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol (2002) 1.04
Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol (2003) 1.02
Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res (2005) 1.02
Results from screening over 9000 mutation-bearing mice for defects in the electroretinogram and appearance of the fundus. Vision Res (2004) 1.02